Tag - Xylyx Bio

Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

Xylyx Bio, Inc., a biotechnology company developing groundbreaking solutions for drug discovery and tissue modeling and repair, announced today that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF). Read more >>

Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. Read more >>

Viviq Skin Health Uses Bioactive Technology To Address Scarring—And Everyday Skincare Concerns

The result is Viviq’s hero product, Advanced Dermal Repair Cream ($185), now available on the brand’s website. Andrea Nye, CEO and president of Xylyx, says that it took “several million dollars” to hone the brand’s patented bioactive ingredient and readying the skincare brand for consumers cost about $400,000. Read more >>

ECM specialists Xylyx-Bio launch skin care brand VIVIQ

Today, executives from Xylyx Bio announced the launch of VIVIQ Skin Health, a consumer brand that leverages proprietary ECM tech. “Our goal at VIVIQ™ is to set a new standard in premium clinical skincare. By combining our scientific expertise in advanced biomaterials with a signature brand aesthetic, VIVIQ is empowering educated consumers to address their specific skin needs,’ says VIVIQ Co-Founder Andrea Nye, in today’s media release about the new brand. Read more >>

Extracellular Matrix: The Secret Sauce of 3D Cell Culture

With 3D cell culture making strong inroads into preclinical studies and basic research, the focus of vendors and investigators alike has turned from discovery to optimization. What kinds of organoids, spheroids, or nondescript 3D cultures work best? What should their cellular composition be?..

When designing 3D cultures—organoids, spheroids, organ-chips, etc.—scientists tend to look for an off-the-shelf answer, much as they do with cell culture media. But in nature ECM composition varies significantly throughout organisms, from tissue to tissue and organ […]

Xylyx Bio and Cell & Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery

New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology. Read more >>

From Conquering COVID-19 to Curing Cancer, New York City Charts the Future of Life Sciences

For the past 25 years, the public and private sectors have worked together to establish New York City as a global leader in life sciences research and innovation. Thanks to that coordinated effort, the city was able to respond to COVID-19 efficiently and effectively, becoming a model for other urban areas as COVID-19 cases peaked across the U.S.—and showcasing a burgeoning life sciences industry in the city that’s poised for future growth…

New York life sciences companies continue to […]

Patient-Derived Organoids Transform Precision Medicine

Advances in cell culture techniques don’t just mean more accurate models, but more personal ones. For decades scientists have been trying to figure out how to grow cells, especially diseased ones, directly from patients, not only to better understand the mechanisms at play, but also to determine the best approach to cure or correct the malfunction. Today, scientists can grow human tumors in a variety of designer mice, some with human immune systems. Read more >>